NCT00979407View on ClinicalTrials.gov

Study to Evaluate Immunological Equivalence Between Two Investigational Influenza Vaccines in Adults (H1N1)

PHASE3CompletedINTERVENTIONAL
Enrollment

336

Participants

Timeline

Start Date

October 12, 2009

Primary Completion Date

November 9, 2009

Study Completion Date

November 4, 2010

Conditions
Influenza
Interventions
BIOLOGICAL

Influenza vaccine GSK2340272A

Two intramuscular injections at Day 0 and Day 21

BIOLOGICAL

Influenza vaccine GSK2340274A

Two intramuscular injections at Day 0 and Day 21

Trial Locations (7)

14033

GSK Investigational Site, Caen

75679

GSK Investigational Site, Paris

75877

GSK Investigational Site, Paris

86000

GSK Investigational Site, Poitiers

93053

GSK Investigational Site, Regensburg

97070

GSK Investigational Site, Würzburg

01762

GSK Investigational Site, Schmiedeberg

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00979407 - Study to Evaluate Immunological Equivalence Between Two Investigational Influenza Vaccines in Adults (H1N1) | Biotech Hunter | Biotech Hunter